Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation
Related Experiment Video
Updated: Aug 23, 2026
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
Hisashi Shimizu1, Masafumi Takahashi, Shin-Ichi Takeda
1Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Tochigi, Japan.
Unlabelled:
BACKGROUND.: Transplant arteriosclerosis is one of the main features of chronic graft failure in organ transplantation. In this article, the authors investigate mechanisms of mycophenolate mofetil (MMF) on prevention of transplant arteriosclerosis in a rat aortic allograft model.
Methods:
Orthotopic rat abdominal aortic transplantation was performed from Brown Norway (RT1) to Lewis (RT1) rats. The recipients were divided into three oral treatment groups: (1). vehicle; (2). MMF40 (40 mg/kg); and (3). MMF20 (20 mg/kg). The authors histologically and immunohistochemically evaluated neointima formation; infiltration of macrophages and T cells; and expression of endothelin (ET)-1, platelet-derived growth factor (PDGF)-B, PDGF receptor-beta (Rbeta), transforming growth factor (TGF) beta 1, and osteopontin (OPN). Using cultured rat vascular smooth muscle cells (VSMC), effects of mycophenolic acid (MPA) on ET-1-induced proliferation and ERK1/2 activation were also examined in vitro.
Results:
In the vehicle group, marked neointima formation was observed, with massive macrophages and T-cell infiltration in neointima, media, and adventitia. Marked expression of ET-1, PDGF-B, PDGFR-beta, TGFbeta1, and OPN were also observed in neointima. In the MMF40 and MMF20 groups, neointima formation was halted, but macrophages and T cells were infiltrated in the adventitia and adhered to the endothelium. In the MMF40 group, medial infiltration by macrophages and T cells and intimal expression of ET-1, PDGF-B, PDGFR-beta, TGFbeta1, and OPN was inhibited compared with the vehicle and MMF20 groups. Furthermore, MPA inhibited ET-1-induced VSMC proliferation but failed to inhibit its ERK1/2 activation.
Conclusions:
MMF treatment might have preventive potential in transplant patients with chronic vasculopathy through inhibition of VSMC proliferation.
Insights
Mycophenolate mofetil (MMF) effectively prevents transplant arteriosclerosis in a rat model by inhibiting vascular smooth muscle cell proliferation. This finding suggests MMF
Area of Science:
- Transplantation immunology
- Vascular biology
- Pharmacology
Background:
- Transplant arteriosclerosis is a primary cause of chronic graft failure.
- Understanding the mechanisms of immunosuppressants like mycophenolate mofetil (MMF) is crucial for preventing this complication.
Purpose of the Study:
- To investigate the preventive effects of MMF on transplant arteriosclerosis in a rat aortic allograft model.
- To elucidate the underlying mechanisms of MMF's action on vascular remodeling and cellular infiltration.
Main Methods:
- Orthotopic rat aortic transplantation model.
- Histological and immunohistochemical analysis of neointima formation, immune cell infiltration, and molecular markers (ET-1, PDGF-B, PDGFR-beta, TGF-beta1, OPN).
- In vitro studies on mycophenolic acid (MPA) effects on vascular smooth muscle cell (VSMC) proliferation and ERK1/2 activation.
Main Results:
- MMF significantly inhibited neointima formation and reduced immune cell infiltration and key molecular marker expression in a dose-dependent manner.
- MMF treatment halted neointima formation but some immune cell infiltration persisted.
- MPA inhibited ET-1-induced VSMC proliferation but not ERK1/2 activation in vitro.
Conclusions:
- MMF demonstrates preventive potential against transplant arteriosclerosis.
- Inhibition of VSMC proliferation is a key mechanism by which MMF exerts its protective effects.
- MMF may be a valuable therapeutic option for managing chronic vasculopathy in transplant recipients.
